LENVIMA is available through Specialty Pharmacies, who will mail the prescription directly to the patient. LENVIMA® can also be dispensed through select eligible physician office/clinic or hospital pharmacies. Please see below for information on accessing LENVIMA®.
LENVIMA® is available through 3 Specialty Pharmacies that will mail Lenvima directly to your patient. Patients receiving LENVIMA® from these Specialty Pharmacies—Accredo, Biologics, or CVS Specialty—will be automatically enrolled in our Patient Support Program upon consent which will provide help throughout the treatment journey.
Please see below for a list of services that are provided through the Patient Support Program.
Accredo Specialty Pharmacy
One of the ways your patient can obtain LENVIMA® is direct from select eligible physician offices/clinics or hospital pharmacies.
LENVIMA® is available through eligible provider offices/clinics or hospital pharmacies. Eligibility information can be obtained through contacting your preferred distributor below. Reimbursement assistance and patient support for patients receiving LENVIMA® from a source other than Accredo, Biologics, or CVS Specialty will be provided by the Eisai Assistance Program. Please call 1-866-61-EISAI (1-866-613-4724) for more information and to enroll your patients in the Patient Support Program.
Please see below for a list of services that are provided through the Eisai Assistance Program.
LENVIMA® has expanded its distribution network to allow for dispensing through select eligible physician office/clinic or hospital pharmacies.
LENVIMA® may be ordered through select distributors.
Please contact your preferred distributor for more information, including eligibility requirements.
A patient starter kit that includes key LENVIMA® educational materials and helpful resources for patients receiving therapy
Ongoing patient communications for monitoring patient progress, adverse reactions, and questions about LENVIMA® therapy
Benefit investigation to help patients understand their coverage for LENVIMA®
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.
LENVIMA is indicated:
Permanently discontinue following an arterial thrombotic event. The safety of resuming after an arterial thromboembolic event has not been established and LENVIMA has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.
Promptly initiate management of diarrhea. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
For more information about LENVIMA, please see available full Prescribing Information.
This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.
LENVIMA® is a registered trademark used by Eisai under license from Eisai R & D Management Co., Ltd.